Selective androgen receptor modulators or SARMs are a novel class of androgen receptor ligands. (The name follows the terminology currently used for similar molecules targeting the estrogen receptor, "selective estrogen receptor modulators," such as Tamoxifen). They are intended to have the same kind of effects as androgenic drugs like anabolic steroids but be much more selective in their action, allowing them to be used for many more clinical indications than the relatively limited legitimate uses that anabolic steroids are currently approved for. 

Currently used androgens for male hormone replacement therapy are typically injectable or skin delivery formulations of testosterone or testosterone esters. Injectable forms of testosterone esters (such as testosterone enanthate, propionate, or cypionate) produce undesirable fluctuations in testosterone blood levels, with overly high levels shortly after injection and overly low afterwards. Skin patches do provide a better blood level profile of testosterone, but skin irritation and daily application still limit their usefulness. Oral androgens are not currently used due to concerns about liver toxicity. SARMs provide the opportunity to design molecules that can be delivered orally, but that selectively target the androgen receptors in different tissues differently. The goal of research in this area is to allow a customized response: tissues that are the target of the therapy will respond as they would to testosterone; other tissues where undesirable side effects are produced will not. Ostarine UK is a non-steroidal, oral selective androgen receptor modulator.

Ostarine has the potential to treat muscle wasting associated with chronic conditions, such as end-stage renal disease, frailty and andropause, as well as muscle wasting associated with acute conditions, such as burns.

Ostarine Sarm like capabilities, provide the benefits of traditional anabolic/androgenic steroids such as testosterone (including increased muscle mass, fat loss, and bone density), while showing a lower tendency to produce unwanted side effects. They are a unique class of molecules currently under development for treatment of many diseases, muscle loss, and joint repair. Ostarine has sown to have far superior anabolic capabilities to any other sarm available on the market today. Ostarine is designed to have anabolic building activity without unwanted androgenic side effects on prostate and skin sebaceous glands.

Overall, clinical laboratory values and hormonal effects determined from the study were consistent with anabolic activity. Ostarine is a new product, its potential is almost unlimited, its versatile enough to be incorporated into PCT therapies, it can be ran in between cycles, and it can be used to huge effect when taken as a standalone anabolic. It binds strongly to the androgen receptor, but without the side effects normally associated with high levels of DHT. It shows considerable properties as a hardening agent just slightly less than those of S4, which itself is 1/3 as androgenic as Testosterone.